

Biocytogen and Hansoh Pharma announce antibody license agreement in China

03 January 2023 | News

Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally.



Biocytogen Pharmaceuticals and Hansoh Pharmaceutical Group have announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialisation globally.

Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.

“The licensed antibodies were selected from Biocytogen’s Project Integrum programmes and generated from our proprietary fully human antibody RenMice target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr Yuelel Shen, President and CEO of Biocytogen.

Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMice™ (RenMab™, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale *in vivo* drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy.